# Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting

> **NCT04425200** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 205 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04425200
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-29
- **Primary completion:** 2020-12-18
- **Final completion:** 2020-12-18
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2021-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04425200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04425200, "Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04425200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*